Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Fate Therapeutics, Inc.NASDAQ: FATE

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $31.38M rose 127.8% year over year, ahead of the -11.7% change in trailing-twelve-month operating expenses. Sequentially, it fell 13.0% from the prior quarter. Over 3 fiscal years it compounded at -28.7% a year.

Context

  • Operating expenses amounted to 2128.3% of revenue in FY2025, up 1355.3 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +127.8% holds above the trailing-twelve-month pace of -11.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.38M-13.0% QoQ
Last fiscal yearDec 2025
$141.45M+34.2% YoY
LTMMar 2026
$113.16M-11.7% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+127.8%——
1 year+34.2%——
3-year CAGR-28.7%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
141.45M USD
Year-over-year change
+34.2%
4-year CAGR
-14.7%

Operating Expenses vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.7% is the 5th highest of 10, against a peer median of -13.7%.
  • Operating expenses amounts to 1791.7% of revenue for FATE, versus a peer median of 640.5%.
FATE Competitors
Operating Expenses for FATE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$373.48M USD+210.2%+63.9%—
ALECAlector, Inc.LTM Mar 2026$125.25M USD-17.6%-16.6%680.1%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$114.57M USD-9.5%+39.9%—
NKTXNkarta, Inc.LTM Mar 2026$113.97M USD-13.7%-2.0%—
FATEFate Therapeutics, Inc.LTM Mar 2026$113.16M USD-11.7%-28.7%1791.7%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$100.47M USD-31.6%-2.4%600.9%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$89.69M USD+109.1%+36.8%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$81.48M USD-22.1%-32.1%—
PEPGPepGen Inc.LTM Mar 2026$79.52M USD-27.0%+10.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 63.08M CHF+100.0%-11.3%—
Peer median (excluding FATE) —-13.7%-2.0%640.5%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.85M96.3M63.53M13.63M6.65M
Cost of Revenue5.85M13.76M157.19M118.53M12.9M
Gross Profit50M82.54M(93.65M)(104.9M)(6.26M)
Gross Margin89.5%85.7%-147.4%-769.6%-94.1%
Research & Development215.52M320.45M172.6M135M107.83M
Selling, General & Admin57.32M84.23M96.86M90.64M46.52M
Operating Expenses266.99M390.93M96.86M105.38M141.45M
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
EBITDA(206.3M)(267.96M)(142.65M)(176.58M)(127.02M)
EBITDA Margin-369.4%-278.3%-224.5%-1295.4%-1911.2%
Operating Income(216.99M)(308.39M)(190.51M)(210.28M)(147.7M)
Operating Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%
Interest Income1.31M5.84M17.19M17.29M11.05M
Interest Expense00000
Other Income / Expenses4.84M26.67M29.58M24.01M11.39M
Income Before Tax(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Pre-Tax Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
Income Tax Expense00000
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (Basic)(2.24)(2.91)(1.64)(1.64)(1.15)
EPS (Diluted)(2.24)(2.91)(1.64)(1.64)(1.15)
Weighted Avg Shares94.75M96.83M98.41M113.69M118.79M
Weighted Avg Shares (Diluted)94.75M96.83M98.41M113.69M118.79M

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.